Skip to content

Arrowhead Research ARWR Net realized gains (losses)

Net realized gains (losses) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$22.58M+1,321%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:RealizedInvestmentGainsLosses.

The official record: Arrowhead Research’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's net realized gains (losses).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's net realized gains (losses)?
Arrowhead Research (ARWR) reported net realized gains (losses) of $19K in Q4 2025.
What is the long-term trend for Arrowhead Research's net realized gains (losses)?
Over 2 years (2022 to 2025), Arrowhead Research's net realized gains (losses) has grown at a -100.0% compound annual growth rate (CAGR), from -$4.43M to $0.
What does net realized gains (losses) mean?
The profit or loss realized from selling investment assets.
How do you interpret net realized gains (losses)?
Positive values indicate successful investment management, while negative values suggest losses on portfolio holdings.
How does net realized gains (losses) compare across companies?
Common for companies with large cash balances invested in marketable securities.